BioRestorative Therapies (BRTX) Net Equity Issued and Repurchased (2010 - 2025)

BioRestorative Therapies (BRTX) has 6 years of Net Equity Issued and Repurchased data on file, last reported at $1.1 million in Q4 2025.

• Quarterly Net Equity Issued and Repurchased changed N/A year-over-year to $1.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.1 million (changed N/A YoY) and the FY2025 annual result came in at $3.1 million, up 241.75% from the prior year.
• Net Equity Issued and Repurchased grew to $1.1 million in Q4 2025, from $927335.0 in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $7.5 million in Q1 2024 to a low of $9.0 in Q3 2023.
• A 3-year average of $1.8 million and a median of $1.0 million in 2025 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 85.6% in 2025, down 85.6% in 2025.
• Tracing BRTX's Net Equity Issued and Repurchased over 3 years: stood at $83073.0 in 2023, then soared by 8961.94% to $7.5 million in 2024, then sank by 85.59% to $1.1 million in 2025.
• The last three Net Equity Issued and Repurchased figures came in at $1.1 million (Q4 2025), $927335.0 (Q2 2025), and $1.1 million (Q1 2025), per Business Quant data.